Abstract:•Antibodies against S2 subunit showed higher activity than the antibodies against RBD.•Glycosylation-removing treatments weekly increased antibody activities.•For the original strain, epitopes distribute on electrically neutral areas, which are positively charged in the Omicron strain.•When pH was adjusted to 5.0, antibody titers against Omicron increased exponentially. Dear Editor,In this Journal, Pascarella and colleagues recently described the value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern.1Pascarella S. Ciccozzi M. Bianchi M. Benvenuto D. Cauda R. Cassone A. The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern.J Infect. 2022; (Epub ahead of print)https://doi.org/10.1016/j.jinf.2022.02.023Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar They interestingly found that the Omicron B.A1 variant has the highest net surface charge of SARS-CoV-2 receptor-binding domain (RBD), which may enhance affinity of Omicron RBD binding to the receptor angiotensin-converting enzyme 2 (ACE2).1Pascarella S. Ciccozzi M. Bianchi M. Benvenuto D. Cauda R. Cassone A. The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern.J Infect. 2022; (Epub ahead of print)https://doi.org/10.1016/j.jinf.2022.02.023Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar However, whether the protein surface electrostatic shift affect antibody activities is still unknown.A vaccine's efficacy or effectiveness against SARS-CoV-2 infection usually ranges from 19% to 99%.2Feikin D.R. Higdon M.M. Abu-Raddad L.J. Andrews N. Araos R. Goldberg Y. et al.Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.Lancet. 2022; 399: 924-944https://doi.org/10.1016/S0140-6736(22)00152-0Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar However, some vaccines show notably lower efficacy, and the reason for this remains unknown. Marked reductions in neutralizing activity have been observed against Omicron relative to the ancestral pseudovirus in plasma from convalescent individuals and from individuals who had been vaccinated against SARS-CoV-2.3Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670https://doi.org/10.1038/s41586-021-04386-2Crossref PubMed Scopus (311) Google Scholar, 4Cao Y. Wang J. Jian F. Xiao T. Song W. Yisimayi A. et al.Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.Nature. 2022; 602: 657-663https://doi.org/10.1038/s41586-021-04385-3Crossref PubMed Scopus (366) Google Scholar, 5Dejnirattisai W. Huo J. Zhou D. Zahradník J. Supasa P. Liu C. et al.SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.Cell. 2022; 185 (467–84.e15)https://doi.org/10.1016/j.cell.2021.12.046Abstract Full Text Full Text PDF PubMed Scopus (241) Google Scholar The SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, 15 of which are in RBD, thereby raising concerns about the effectiveness of available vaccines and antibody-based therapeutics.3Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670https://doi.org/10.1038/s41586-021-04386-2Crossref PubMed Scopus (311) Google Scholar In addition to these mutations, the other possible reasons for the considerable decline in the neutralizing activity against Omicron have yet to be documented.In this study, we computed sequence-based antibody epitopes on spike proteins of SARS-CoV-2. Four epitopes with high surface accessible scores have been found and named #RBD, #CS (S1/S2 cleavage site), #S2–1 (S2 subunit-1) and #S2–2 (S2 subunit-2), respectively (Fig. 1A and Supplementary Fig. 1, and Supplementary Table 1). Then these epitopes were synthesized chemically. The ascites production of monoclonal antibodies against these epitopes was generated by inoculation of mice. However, unlike the other three epitopes, the epitope #CS failed to generate any ascites antibodies, which may be because the cleavage impairs its antigenicity.Mouse monoclonal antibody against the epitope #RBD showed a relatively high endpoint (dilution) titer against the SARS-CoV-2 original strain (Fig. 1B). A human neutralizing monoclonal antibody, CV30,6Seydoux E. Homad L.J. MacCamy A.J. Parks K.R. Hurlburt N.K. Jennewein M.F. et al.Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation.Immunity. 2020; 53 (98–105.e5)https://doi.org/10.1016/j.immuni.2020.06.001Abstract Full Text Full Text PDF PubMed Scopus (208) Google Scholar,7Hurlburt N.K. Seydoux E. Wan Y.H. Edara V.V. Stuart A.B. Feng J. et al.Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.Nat Commun. 2020; 11: 5413https://doi.org/10.1038/s41467-020-19231-9Crossref PubMed Scopus (82) Google Scholar also in complex with the RBD, showed a much higher endpoint titer to the original strain than mouse anti-#RBD antibody (Fig. 1C). This may be because CV30 binds more residues (32 residues) than the epitope #RBD (14 residues). However, endpoint titers of both antibodies against RBD were significantly lower when binding to the Omicron S protein, by a factor of 10 for CV30. This is consistent with a previous report stating that the neutralizing activity against Wuhan-Hu-1 and retained detectable neutralization against Omicron, with decreases about 21–39-fold.3Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670https://doi.org/10.1038/s41586-021-04386-2Crossref PubMed Scopus (311) Google Scholar Five of 9 residues binding to CV30 at the C-terminal of RBD were found to be mutated in Omicron (Supplementary Fig. 1). This might be an important reason for its decreased binding activity.The epitope #S2–1 with the highest SA score of 4.431 is located on the interface between subunits S1 and S2, which might be uncovered by transmembrane protease serine 2 (TMPRSS2) cleavage (Supplementary Fig. 2). However, neither TMPRSS2 nor its inhibitor Camostat8Hoffmann M. Kleine-Weber H. Schroeder S. Krüger N. Herrler T. Erichsen S. et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell. 2020; 181: 271-280https://doi.org/10.1016/j.cell.2020.02.052Abstract Full Text Full Text PDF PubMed Scopus (10259) Google Scholar affected antibody activity (Supplementary Fig. 2).Unexpectedly, mouse monoclonal antibody against the epitope #S2–2 showed the highest endpoint (dilution) titer to the original strain (3 times higher than the antibody against #RBD; Fig. 1B). Human monoclonal antibody against S2 subunit confirmed this finding (2 times higher than the antibody titer against S1 subunit; Fig. 1C). The unexpectedly high activity of non-neutralizing antibodies against S2 subunit were consistent with the fact that the vaccine efficacies against severe disease are usually higher than 90%, no matter how low the vaccine efficacies against SARS-CoV-2 infection are.2Feikin D.R. Higdon M.M. Abu-Raddad L.J. Andrews N. Araos R. Goldberg Y. et al.Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.Lancet. 2022; 399: 924-944https://doi.org/10.1016/S0140-6736(22)00152-0Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar Nevertheless, activities of both anti-S2 antibodies declined 11–23-fold when binding with Omicron S protein (Fig. 1BC).Possible reasons for the dramatically reduced antibody activity against the Omicron variant were further investigated. Previous studies have suggested that N-linked glycosylation on the S protein may compromise its antibody activities.9Vankadari N. Wilce J.A. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26.Emerg Microbes Infect. 2020; 9: 601-604https://doi.org/10.1080/22221751.2020.1739565Crossref PubMed Scopus (383) Google Scholar,10Walls A.C. Park Y.J. Tortorici M.A. Wall A. McGuire A.T. Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.Cell. 2020; 181: 281-292https://doi.org/10.1016/j.cell.2020.02.058Abstract Full Text Full Text PDF PubMed Scopus (4626) Google Scholar Most SARS-CoV-2 epitopes are shielded by glycans, and only areas of the protein surface at the apex of the S1 domain (RBD region) are not surrounded by glycosylation sequons (Fig. 1A). Consistent with the structure analysis, oligosaccharide-removing treatments involving PNGase F increased all antibody titers, especially for anti-S2 antibodies (Fig. 1DE). However, after PNGase F treatments, antibody titers against Omicron were still much lower than those against the original strain (Fig. 1DE).Given that all the three epitopes #RBD, #S2–1, and #S2–2 are completely conserved in all SARS-CoV-2 strains (Supplementary Fig. 1), the large decline in the antibody activity against Omicron cannot be attributed to the mutations. We noticed that 11 residues had been substituted into the alkaline amino acid on Omicron S protein, which may change the electrostatic potential on the surface of the protein. We computed the electrostatic potential on the S protein. The surface of the Omicron S protein is uniformly positively charged. However, a large part of original SARS-CoV-2 S protein surface is electrically neutral or negatively charged, but its RBD is positively charged (Fig. 2A). For the original strain, epitopes #RBD and #S2–2 distribute on electrically neutral areas, which are positively charged in the Omicron strain. When the pH value of the binding system was adjusted to 5.0 (the positive charge could be neutralized), antibody titers against Omicron increased exponentially. This effect was doubled for anti-RBD antibodies, 7–11-fold increases for anti-S2 antibodies (Fig. 2BC). However, pH 9.0 decreased all antibody activity (Fig. 2DE).Fig. 2Shift in electrostatic potential affect antibody activities against SARS-CoV-2 original strain and Omicron variant. (A) Electrostatic potential of SARS-CoV-2 S. The red-to-blue color on the molecular surface indicates the electrostatic potential (red: −1.8; blue: 1.8). Epitopes #RBD, #S2–1, and #S2–2 and CV30 binding residues are marked with the dark blue color. (B) Endpoint titers of mouse anti-#RBD, anti-#S2–1 and anti-#S2–2 antibodies at pH 5.0. (C) Endpoint titers of human anti-RBD, anti-S1, and anti-S2 antibodies at pH 5.0. (D) Endpoint titers of mouse anti-#RBD, anti-#S2–1, and anti-#S2–2 antibodies at pH 9.0. (E) Endpoint titers of human anti-RBD, anti-S1, and anti-S2 antibodies at pH 9.0. Bars represent standard deviations of three independent replicates. Values followed by different letters are significantly different at P < 0.05 according to Duncan's multiple range test.View Large Image Figure ViewerDownload Hi-res image Download (PPT)The large decline in antibody activity against Omicron RBD (neutralization) may be attributed to both residue mutations and the shift in electrostatic potential. The large decline in antibody activity against the Omicron S2 subunit (non-neutralizing antibody activity) may be mainly attributable to a shift in electrostatic potential on the surface of the protein. Because the heterogeneity in antigen surface-charge distribution causes charge-related heterogeneity in monoclonal antibodies,11Vlasak J. Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods.Curr Pharm Biotechnol. 2008; 9: 468-481https://doi.org/10.2174/138920108786786402Crossref PubMed Scopus (197) Google Scholar new vaccines against the full-length Omicron S protein may be developed that have both negatively charged neutralizing antibodies and negatively charged non-neutralizing antibodies with high affinity to the Omicron variant. Dear Editor, In this Journal, Pascarella and colleagues recently described the value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern.1Pascarella S. Ciccozzi M. Bianchi M. Benvenuto D. Cauda R. Cassone A. The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern.J Infect. 2022; (Epub ahead of print)https://doi.org/10.1016/j.jinf.2022.02.023Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar They interestingly found that the Omicron B.A1 variant has the highest net surface charge of SARS-CoV-2 receptor-binding domain (RBD), which may enhance affinity of Omicron RBD binding to the receptor angiotensin-converting enzyme 2 (ACE2).1Pascarella S. Ciccozzi M. Bianchi M. Benvenuto D. Cauda R. Cassone A. The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern.J Infect. 2022; (Epub ahead of print)https://doi.org/10.1016/j.jinf.2022.02.023Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar However, whether the protein surface electrostatic shift affect antibody activities is still unknown. A vaccine's efficacy or effectiveness against SARS-CoV-2 infection usually ranges from 19% to 99%.2Feikin D.R. Higdon M.M. Abu-Raddad L.J. Andrews N. Araos R. Goldberg Y. et al.Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.Lancet. 2022; 399: 924-944https://doi.org/10.1016/S0140-6736(22)00152-0Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar However, some vaccines show notably lower efficacy, and the reason for this remains unknown. Marked reductions in neutralizing activity have been observed against Omicron relative to the ancestral pseudovirus in plasma from convalescent individuals and from individuals who had been vaccinated against SARS-CoV-2.3Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670https://doi.org/10.1038/s41586-021-04386-2Crossref PubMed Scopus (311) Google Scholar, 4Cao Y. Wang J. Jian F. Xiao T. Song W. Yisimayi A. et al.Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.Nature. 2022; 602: 657-663https://doi.org/10.1038/s41586-021-04385-3Crossref PubMed Scopus (366) Google Scholar, 5Dejnirattisai W. Huo J. Zhou D. Zahradník J. Supasa P. Liu C. et al.SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.Cell. 2022; 185 (467–84.e15)https://doi.org/10.1016/j.cell.2021.12.046Abstract Full Text Full Text PDF PubMed Scopus (241) Google Scholar The SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, 15 of which are in RBD, thereby raising concerns about the effectiveness of available vaccines and antibody-based therapeutics.3Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670https://doi.org/10.1038/s41586-021-04386-2Crossref PubMed Scopus (311) Google Scholar In addition to these mutations, the other possible reasons for the considerable decline in the neutralizing activity against Omicron have yet to be documented. In this study, we computed sequence-based antibody epitopes on spike proteins of SARS-CoV-2. Four epitopes with high surface accessible scores have been found and named #RBD, #CS (S1/S2 cleavage site), #S2–1 (S2 subunit-1) and #S2–2 (S2 subunit-2), respectively (Fig. 1A and Supplementary Fig. 1, and Supplementary Table 1). Then these epitopes were synthesized chemically. The ascites production of monoclonal antibodies against these epitopes was generated by inoculation of mice. However, unlike the other three epitopes, the epitope #CS failed to generate any ascites antibodies, which may be because the cleavage impairs its antigenicity. Mouse monoclonal antibody against the epitope #RBD showed a relatively high endpoint (dilution) titer against the SARS-CoV-2 original strain (Fig. 1B). A human neutralizing monoclonal antibody, CV30,6Seydoux E. Homad L.J. MacCamy A.J. Parks K.R. Hurlburt N.K. Jennewein M.F. et al.Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation.Immunity. 2020; 53 (98–105.e5)https://doi.org/10.1016/j.immuni.2020.06.001Abstract Full Text Full Text PDF PubMed Scopus (208) Google Scholar,7Hurlburt N.K. Seydoux E. Wan Y.H. Edara V.V. Stuart A.B. Feng J. et al.Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.Nat Commun. 2020; 11: 5413https://doi.org/10.1038/s41467-020-19231-9Crossref PubMed Scopus (82) Google Scholar also in complex with the RBD, showed a much higher endpoint titer to the original strain than mouse anti-#RBD antibody (Fig. 1C). This may be because CV30 binds more residues (32 residues) than the epitope #RBD (14 residues). However, endpoint titers of both antibodies against RBD were significantly lower when binding to the Omicron S protein, by a factor of 10 for CV30. This is consistent with a previous report stating that the neutralizing activity against Wuhan-Hu-1 and retained detectable neutralization against Omicron, with decreases about 21–39-fold.3Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670https://doi.org/10.1038/s41586-021-04386-2Crossref PubMed Scopus (311) Google Scholar Five of 9 residues binding to CV30 at the C-terminal of RBD were found to be mutated in Omicron (Supplementary Fig. 1). This might be an important reason for its decreased binding activity. The epitope #S2–1 with the highest SA score of 4.431 is located on the interface between subunits S1 and S2, which might be uncovered by transmembrane protease serine 2 (TMPRSS2) cleavage (Supplementary Fig. 2). However, neither TMPRSS2 nor its inhibitor Camostat8Hoffmann M. Kleine-Weber H. Schroeder S. Krüger N. Herrler T. Erichsen S. et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell. 2020; 181: 271-280https://doi.org/10.1016/j.cell.2020.02.052Abstract Full Text Full Text PDF PubMed Scopus (10259) Google Scholar affected antibody activity (Supplementary Fig. 2). Unexpectedly, mouse monoclonal antibody against the epitope #S2–2 showed the highest endpoint (dilution) titer to the original strain (3 times higher than the antibody against #RBD; Fig. 1B). Human monoclonal antibody against S2 subunit confirmed this finding (2 times higher than the antibody titer against S1 subunit; Fig. 1C). The unexpectedly high activity of non-neutralizing antibodies against S2 subunit were consistent with the fact that the vaccine efficacies against severe disease are usually higher than 90%, no matter how low the vaccine efficacies against SARS-CoV-2 infection are.2Feikin D.R. Higdon M.M. Abu-Raddad L.J. Andrews N. Araos R. Goldberg Y. et al.Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.Lancet. 2022; 399: 924-944https://doi.org/10.1016/S0140-6736(22)00152-0Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar Nevertheless, activities of both anti-S2 antibodies declined 11–23-fold when binding with Omicron S protein (Fig. 1BC). Possible reasons for the dramatically reduced antibody activity against the Omicron variant were further investigated. Previous studies have suggested that N-linked glycosylation on the S protein may compromise its antibody activities.9Vankadari N. Wilce J.A. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26.Emerg Microbes Infect. 2020; 9: 601-604https://doi.org/10.1080/22221751.2020.1739565Crossref PubMed Scopus (383) Google Scholar,10Walls A.C. Park Y.J. Tortorici M.A. Wall A. McGuire A.T. Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.Cell. 2020; 181: 281-292https://doi.org/10.1016/j.cell.2020.02.058Abstract Full Text Full Text PDF PubMed Scopus (4626) Google Scholar Most SARS-CoV-2 epitopes are shielded by glycans, and only areas of the protein surface at the apex of the S1 domain (RBD region) are not surrounded by glycosylation sequons (Fig. 1A). Consistent with the structure analysis, oligosaccharide-removing treatments involving PNGase F increased all antibody titers, especially for anti-S2 antibodies (Fig. 1DE). However, after PNGase F treatments, antibody titers against Omicron were still much lower than those against the original strain (Fig. 1DE). Given that all the three epitopes #RBD, #S2–1, and #S2–2 are completely conserved in all SARS-CoV-2 strains (Supplementary Fig. 1), the large decline in the antibody activity against Omicron cannot be attributed to the mutations. We noticed that 11 residues had been substituted into the alkaline amino acid on Omicron S protein, which may change the electrostatic potential on the surface of the protein. We computed the electrostatic potential on the S protein. The surface of the Omicron S protein is uniformly positively charged. However, a large part of original SARS-CoV-2 S protein surface is electrically neutral or negatively charged, but its RBD is positively charged (Fig. 2A). For the original strain, epitopes #RBD and #S2–2 distribute on electrically neutral areas, which are positively charged in the Omicron strain. When the pH value of the binding system was adjusted to 5.0 (the positive charge could be neutralized), antibody titers against Omicron increased exponentially. This effect was doubled for anti-RBD antibodies, 7–11-fold increases for anti-S2 antibodies (Fig. 2BC). However, pH 9.0 decreased all antibody activity (Fig. 2DE). The large decline in antibody activity against Omicron RBD (neutralization) may be attributed to both residue mutations and the shift in electrostatic potential. The large decline in antibody activity against the Omicron S2 subunit (non-neutralizing antibody activity) may be mainly attributable to a shift in electrostatic potential on the surface of the protein. Because the heterogeneity in antigen surface-charge distribution causes charge-related heterogeneity in monoclonal antibodies,11Vlasak J. Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods.Curr Pharm Biotechnol. 2008; 9: 468-481https://doi.org/10.2174/138920108786786402Crossref PubMed Scopus (197) Google Scholar new vaccines against the full-length Omicron S protein may be developed that have both negatively charged neutralizing antibodies and negatively charged non-neutralizing antibodies with high affinity to the Omicron variant. The authors declare no competing interests. We thank Abmart Comp. (Shanghai, China) for generating mouse monoclonal antibodies against synthetic epitopes, and LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript. This work was supported by the Sichuan Province Youth Science and Technology Innovation Team ( 20CXTD0062 to S. Yuan) and the Applied Basic Research Program of Sichuan Province ( 2020YJ0410 to Z.-W. Zhang). Appendix. Supplementary materials Download .pdf (4.97 MB) Help with pdf files Download .pdf (4.97 MB) Help with pdf files

Abstract:The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has caused a global health emergency. With increasing numbers of infected people and deaths worldwide reported daily since the beginning of the year, we have to urgently focus on a new pandemic caused by the SARS-CoV-2, a betacoronavirus related to SARS-CoV. We have to urgently learn more about this virus, its ways of transmission to spread infection so fast all over the world, the pathomechanisms involved in human infection and intracellular entry, the consecutive spreading within the body, and finally the factors that determine the difference between a mild or even asymptomatic infection in one and a deadly disease in another patient.1Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [published online ahead of print February 19, 2020]. Allergy. https://doi.org/10.1111/all.14238.Google Scholar Obviously, the age and health condition of the infected person including hypertension, diabetes, and cardiovascular disease play an important role in the clinical course of a coronavirus disease. Urgently, we need to find adequate treatments, and there might be more than adequate masks and social distancing on the one hand and vaccination on the other hand. SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), is highly contagious. It is of utmost importance to understand how the virus succeeds in infecting an individual person and entering first an outer surface cell and starts replicating, because this might offer therapeutic approaches in the near future. The major entrance door to the patient obviously is the nose and nasopharynx. In a study of infected patients, SARS-CoV-2 viral load was detected higher in the nose than in the throat.2Zou L. Ruan F. Huang M. Liang L. Huang H. Hong Z. et al.SARS-CoV-2 viral load in upper respiratory specimens of infected patients.N Engl J Med. 2020; 382: 1177-1179Crossref PubMed Scopus (3423) Google Scholar Also, we have painfully learned from the fact that many health care professionals, specifically also ear-nose-and-throat (ENT) specialists, died from COVID-19.3Patel Z.M. Fernandez-Miranda J. Hwang P.H. Nayak J.V. Dodd R. Sajjadi H. et al.Letter: Precautions for endoscopic transnasal skull base surgery during the COVID-19 pandemic.Neurosurgery. 2020 Apr 15; (nyaa125. doi: 10.1093/neuros/nyaa125)Google Scholar Surgery in the nose of an infected patient has been shown to not only put the surgeon at risk, but everyone in the operation room, specifically when drills and endoscopes are used and aerosols are formed during the surgery. Furthermore, it was quite apparent early on that one of the early symptoms of COVID-19 is a loss of smell and consecutively of taste, clearly differentiating the SARS-CoV-2 infection from a normal common cold or a flu. Although most reports are still anecdotal, anosmia/hyposmia was reported in up to 60% of the patients, even among those without typical symptoms such as cough, fever, or dyspnea (https://www.entuk.org/categories/covid-19). This led to the statements by the American and British ENT societies, proposing a particular attention to recent-onset olfactory dysfunction as an early possible sign of COVID-19. It has been confirmed later that olfactory epithelial support cells and stem cells express both of these genes discussed below, as do cells in the nasal respiratory epithelium.4Brann D. Tsukahara T. Weinreb C. Logan D.W. Datta S.R. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients.bioRxiv. 2020; Google Scholar What do we know about upper airway conditions such as chronic rhinosinusitis (CRS) with or without polyps, or allergic rhinitis; would these diseases increase the risk of infection? These are diseases affecting 10% to 30% of the population in the United States and Europe, and most often type 2 immune reactions associated with an anyway weak immune defense and reduced IFN production upon infection. We have learned, also from the related coronavirus SARS-CoV, causing SARS outbreak in 2003, that SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) exposed at the airway surface and uses it as receptor (Fig 1 ).5Hoffmann M. Kleine-Weber H. Schroeder S. Krüger N. Herrler T. Erichsen S. et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell. 2020; 181: 271-280.e8Abstract Full Text Full Text PDF PubMed Scopus (13243) Google Scholar To invade the cell, there is need for another player, the transmembrane protease TMPRSS2, a serine protease expressed in airway epithelial cells, mucosal glands, and inflammatory cells such as macrophages, that activates the viral S protein and enables human airway cell entry.6Kam Y.W. Okumura Y. Kido H. Ng L.F. Bruzzone R. Altmeyer R. Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro.PLoS One. 2009; 4e7870Crossref PubMed Scopus (125) Google Scholar How is this receptor and the protease regulated in the nasal cavity, and how does that change with age, sex, or disease status,1Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [published online ahead of print February 19, 2020]. Allergy. https://doi.org/10.1111/all.14238.Google Scholar and would that possibly explain some of the questions posed above? Of 110 patients hospitalized for SARS-CoV-2 infection from Wuhan and Zhuhai hospitals, only 1 patient reported CRS, 2 allergic rhinitis, and 1 chronic pharyngitis as preexisting diseases (Li Jian, personal communication, 2020). During infection, only 2 patients reported pharyngeal dryness and pain, and 1 nasal obstruction as symptoms, whereas 5 reported loss of smell, in accordance with recent reports.1Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [published online ahead of print February 19, 2020]. Allergy. https://doi.org/10.1111/all.14238.Google Scholar,4Brann D. Tsukahara T. Weinreb C. Logan D.W. Datta S.R. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients.bioRxiv. 2020; Google Scholar Differences in interviewing the patients may account for different prevalences of loss of smell. In the data sets from healthy individuals generated by the Human Cell Atlas consortium, when assessing the RNA expression of the coronavirus receptor (ACE2) as well as the viral S protein priming protease TMPRSS2, nasal epithelial cells displayed the highest ACE2 PCR measurements of all cells analyzed.7Sungnak W, Huang N, Bécavin C, Berg M, HCA Lung Biological Network. SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways [published online ahead of print March 13, 2020]. arXiv preprint arXiv:2003.06122.Google Scholar,8Ziegler C. Allon S.J. Nyquist S.K. Mbano I. Miao V.N. Cao Y. et al.SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues. Cell.https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3555145Date accessed: April 2, 2020Google Scholar However, it needs to be mentioned that the protein expression was not demonstrated. Furthermore, the corona virus receptor ACE2 may be an IFN-stimulated gene.8Ziegler C. Allon S.J. Nyquist S.K. Mbano I. Miao V.N. Cao Y. et al.SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues. Cell.https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3555145Date accessed: April 2, 2020Google Scholar This could imply that any viral infection could facilitate SARS-CoV-2 infection by releasing IFNs and upregulating ACE2. However, type 2 immune conditions such as CRS without nasal polyps (CRSwNP) with a pronounced type 2 immune reaction and a deficit in IFNs might rather downregulate ACE2 expression. In fact, we observed a reduced expression of ACE2 in nasal polyp disease versus control tissue based on RT-PCR in 20 nasal samples (O. Krysko, N. Zhang, and C. Bachert, unpublished data, 2020). In a rat model of allergic asthma, the expression of ACE2 in lungs was decreased compared with negative control.9Dhawale V.S. Amara V.R. Karpe P.A. Malek V. Patel D. Tikoo K. Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model.Toxicol Appl Pharmacol. 2016; 306: 17-26Crossref PubMed Scopus (52) Google Scholar In summary, these findings might suggest that type 2 inflammatory condition in the airways could have a protective effect against COVID-19 infection or its severity. However, further studies are warranted to clarify causal relationships. Meanwhile, it also needs to be clarified whether ACE2 expression in the nasal tissues was influenced by intranasal corticosteroid (INCS) treatment often used in these patients. This leads us to the question whether treatment in patients with allergic rhinitis, normally INCS, or in severe patients with CRSwNP, nowadays including biologics to suppress type 2 immune reactions, should be continued in case of a SARS-CoV-2 infection. The Global INitiative for Asthma statement (https://ginasthma.org/recommendations-for-inhaled-asthma-controller-medications/) advised that patients with asthma should not stop their prescribed inhaled corticosteroid controller medication (or prescribed oral corticosteroids), because stopping inhaled corticosteroid may lead to the potentially dangerous worsening of asthma, and avoiding oral corticosteroids during severe asthma attacks may have serious consequences. The administration of oral corticosteroids for COVID-19 lung injury is not advised by the World Health Organization (https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected); however, the World Health Organization does not discourage the use of corticosteroids when indicated independently from COVID-19. Referring to the Global INitiative for Asthma statement, the Allergic Rhinitis and its Impact on Asthma-European Academy of Allergology and Clinical Immunology statement authored by Bousquet et al10Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement [published online ahead of print March 31, 2020]. Allergy. https://doi.org/10.1111/all.14302.Google Scholar based on a Delphi process advised to continue INCS treatment for allergic rhinitis, because there is no current evidence that INCS would increase infectivity or symptoms of SARS-CoV-2 infection. However, discontinuation of corticosteroid therapy could induce more coughing or more sneezing because of the loss of control of inflammation, and therefore may increase the risk of infection of so far healthy subjects. Sneezing may spread the virus over several meters, distancing of 2 m clearly is not enough, and face masks are advised in this situation. SARS-CoV-2 may also infect patients with severe asthma and CRSwNP, who might be under treatment with a type 2 biologic drug such as dupilumab, omalizumab, or mepolizumab. Again, no data are available for any on the type 2 biologics today, but balancing the risk of losing disease control and the lack of evidence or expectation of increased infectivity or mortality, there already are recommendations to continue the treatment with biologics and even start new treatments (eg, from the German Allergy Society [https://dgaki.de/]). In fact, in a situation in which surgery of the sinuses is not advised to prevent infection of the operation theater staff, a biologic may in fact offer a possibility to severe patients with nasal polyps. We (Ulrike Förster, Charite Berlin) actually just report on a patient on dupilumab for recurrent severe CRSwNP, who developed a SARS-CoV-2 infection without any additional difficulties. The smell, which was restored after dupilumab, disappeared as the only symptom under the CoV infection, but returned fast thereafter. No other symptoms or changes have been observed. The emergence of COVID-19 will bring a major change to our practice. However, we begin to recognize that diseases of the upper airways or their management by corticosteroids and biologics do not seem to increase the risk of infection nor the risk for severe COVID-19. A narrow follow-up certainly is advised. Because health care workers at ENT departments are prone to the viral exposure, a consensus is needed very urgently on protective measures for the professionals. In research perspective, because the airway passage of nose and nasopharynx is the main entry for respiratory viruses including the SARS-CoV 2, the expression and its regulation of the ACE2 receptor and the TMPRSS2 protease are key topics for research and targets for interventions. However, given the potential of new respiratory viral outbreaks in the future, further attention should be given to how to modulate protective roles of upper airway mucosa against different viral infections. COVID-19 and upper respiratory tract: Collecting swab specimens from patients inhaling corticosteroidsJournal of Allergy and Clinical ImmunologyVol. 146Issue 6PreviewJian et al1 in a recent article refer to the immune reaction of the upper respiratory tract (URT) in patients infected by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 (coronavirus disease 2019 [COVID-19] pandemic). The authors wonder about the consequences of inhaled corticosteroids (ICSs) on immune reaction. We share the queries of Jian et al, from a practical point of view. Full-Text PDF

Tackling COVID19 by Exploiting Pre-existing Cross-Reacting Spike-Specific Immunity

Surface Electrostatic Shift on Spike Protein Decreased Antibody Activities Against SARS-CoV-2 Omicron Variant

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

COVID-19-neutralizing antibodies predict disease severity and survival

Editorial: Cross-reactive immunity and COVID-19

The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses

Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike

Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins

The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Novel b-cell epitopes of non-neutralizing antibodies in the receptor-binding domain of the S-protein of SARS-CoV-2 with differing effects on the severity of the course of COVID-19

Perspective: COVID-19, Implications of Nasal Diseases and Consequences for Their Management.

High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients

Cross-reactive Antibody Against Human Coronavirus OC43 Spike Protein Correlates with Disease Severity in COVID-19 Patients: a Retrospective Study.

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens

Dynamics and significance of the antibody response to SARS-CoV-2 infection

Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection.

Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus